mProX™ Human CCR8 Stable Cell Line

Product Information

Target Protein

CCR8

Target Family

Chemokine Family

Target Protein Species

Human

Host Cell Type

5637;CHO-K1;HEK293

Target Classification

GPCR Cell Lines

Target Research Area

Infectious Research;Cardiovascular Research

Related Diseases

Molluscum Contagiosum;Kaposi Sarcoma

Gene ID

Human: 1237

UniProt ID

Human: P51685

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

CCR8, known as the C-C chemokine receptor type 8, is another protein that has garnered attention in the scientific community. This receptor has been identified as playing a significant role in the function of regulatory T cells (Tregs) within tumor tissues. One of the groundbreaking studies in this domain highlighted the potential of CCR8-targeted therapy to deplete tumor-promoting Tregs, thereby eliciting potent antitumor immunity. Furthermore, the CCR8 receptor has been associated with the immunosuppressive environment in lung cancer, emphasizing its role in cytotoxic T lymphocyte suppression. Another study revealed the significance of CCR8+ Tregs in immunosuppression in lung cancer, suggesting the potential value of CCR8-targeted therapy for cancer treatment. Given these findings, CCR8 emerges as a potential therapeutic target in oncology, particularly in understanding tumor immunity and developing targeted interventions.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human CCR8 Stable Cell Line (S01YF-0923-PY41). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Michelle (Verified Customer)

How does the chemokine CCL18 interact with its receptor CCR8 in human microglial cells? Jul 18 2020

chat Patrick Liam (Creative Biolabs Scientific Support)

CCL18 may exhibit anti-inflammatory activity and activate the phagocytic function of microglia, playing a role in neural development, homeostasis, and repair mechanisms. Jul 18 2020

chat Christopher (Verified Customer)

What are the implications of GB2101, an anti-CCR8 antibody, in cancer treatment? Jul 27 2021

chat Patrick Liam (Creative Biolabs Scientific Support)

GB2101 is a novel monoclonal antibody that binds specifically to CCR8 with high affinity. It effectively blocks the CCL1-CCR8 pathway and suppresses tumor growth in vivo, making it a promising preclinical candidate for treating various tumor types. Jul 27 2021

Published Data

Fig.1 CCR8 plays an essential role in facilitating the migration and invasion of breast cancer cells through its interaction with the chemokine CCL18.

In a 24-hour treatment, 5637 bladder cancer cells underwent exposure to CCL18 (50 ng/ml), CCL18 combined with NT shRNA, or CCL18 combined with CCR8 shRNA. Assessments of invasion (via Transwell assays, A and B) and migration (through wound healing assays, C and D) were conducted, each observed at a ×100 magnification. Statistically significant differences were noted (*P<0.05) compared to the NC group, while (**P<0.05) contrasts were identified in comparison to the CCL18 + NT shRNA group. Notations: CCL18, chemokine (C-C motif) ligand 18; CCR8, chemokine (C-C motif) receptor 8; NC, normal control; NT, non-target; shRNA, short hairpin RNA.

Ref: Liu, Xiaoqiang, et al. "CCL18 enhances migration, invasion and EMT by binding CCR8 in bladder cancer cells." Molecular medicine reports 19.3 (2019): 1678-1686.

Pubmed: 30592282

DOI: 10.3892/mmr.2018.9791

Research Highlights

Sun T, et al. "Oxamate enhances the efficacy of CAR-T therapy against glioblastoma via ." Journal of experimental & clinical cancer research : CR, 2023.
Chimeric antigen receptor (CAR)-T immunotherapy has shown limited success in treating solid tumors. One contributing factor is the immunosuppressive microenvironment created by excess lactate produced by tumor glycolysis. However, the specific mechanism by which lactate induces immunosuppression remains unclear. In this study, the researchers used flow cytometry and immunohistochemical staining to analyze immunocyte subpopulations and molecular characteristics in orthotopic xenografts of nude mice. They found that treatment with oxamate, a lactate dehydrogenase A inhibitor, in combination with T or CAR-T cell injection, promoted immune activation of tumor-infiltrating CAR-T cells and increased infiltration of regulatory T cells in a glioblastoma mouse model. Further experiments revealed that lactate upregulated the expression of specific immune molecules in both lactate-treated cells and glioma stem cell-co-cultured CD4+ T cells and macrophages. This effect was mediated through histone H3K18 lactylation. These findings suggest that inhibiting lactate production may be a potential strategy for enhancing CAR-T function in glioblastoma therapy.
Pubmed: 37770937 DOI: 10.1186/s13046-023-02815-w

Chu YT, et al. "Interplay of Chemokines Receptors, Toll-like Receptors, and Host Immunological ." Biomedicines, 2023.
The study investigated the correlation between different chemokine receptors and specific T helper (TH) cell responses. Results showed that CCR5 was associated with TH1 responses, CCR1 with TH1-like responses, CCR4 with TH2 and TH9 responses in basophils, CCR3 with TH2 and TH9 responses in eosinophils, CCR10 with TH22 responses, CCR6 with TH17 responses, CXCR3 with THalphabeta responses, CCR8 with regulatory T cells (Treg), and CCR2 with TH3 responses. This information is significant in identifying biomarkers for different immune cells and understanding the underlying mechanisms of immune pathways. Adequate understanding of the chemokine and Toll-like receptor system is crucial for comprehending the function of both innate and adaptive immune responses.
Pubmed: 37760825 DOI: 10.3390/biomedicines11092384